Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model
Efficacy and Toxicity of CSIC abd Retrocylin in the SIV Virus Challenge Model
批准号:
8380861
负责人:
Preston A Marx
金额:
$41.33万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2014-08-31
关键词:
AdultAnimal HusbandryAnimal ModelAnimal WelfareAnimalsClinical TrialsCodeColposcopyDoseDrug FormulationsDrug resistanceEnvironmentEvaluationFemaleGenetic RecombinationGoalsHIVHIV Entry InhibitorsHIV-1HeadHousingHumanHybridsImplantIn VitroInfectionInflammationLaboratoriesMacacaMacaca mulattaModelingMonitorMonkeysPersonal CommunicationPharmaceutical PreparationsPhasePreventionPrevention approachPrimatesPrincipal InvestigatorProceduresPublishingRNA-Directed DNA PolymeraseReportingResearchResourcesReverse Transcriptase InhibitorsRouteSIVSerumSexual TransmissionSiliconesSurfaceTechnical ExpertiseTestingTimeTissuesTopical applicationToxic effectUnited States National Institutes of HealthVaginaVirusVirus DiseasesWashingtonWorkabsorptionbaseclinical carecost effectivedata exchangedesignefficacy testingevaluation/testingexperiencein vivoinhibitor/antagonistinterestmicrobicidenon-nucleoside reverse transcriptase inhibitorsnonhuman primatenovel strategiesprogramsrepositoryresearch studyretrocyclinsimian human immunodeficiency virustransmission processvaginal microbicidevaginal transmission
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project 4 will use the SHIV/female rhesus macaque model to evaluate the toxicity and efficacy of 2 candidate
vaginal microbicides, RC-101 and CSIC. Two different SHIVs will be required because RC-101 is HIV-1 env
specific and CSIC is HIV-1 RT specific. SHIV162p4 carries the HIV-1 env and RT-SHIV carries the HIV-1
RT coding region. Project 4 will interact closely with the projects 1-3 and the cores that will carry out the in
vitro studies needed to validate RC-101 and CSIC for use in the monkey model. There are 5 aims:
1. To assess vaginal and systemic toxicity of CSIC and RC-101 in adult rhesus macaques. Vaginal
colposcopy will assess inflammation associated with drugs in the silicone rings that will be specially made for
use in macaques. Sera will be tested for absorption of drug(s) and vaginal washes will be used to assess
release of drug into the vaginal vault. 2. To determine the minimal infectious dose for RT-SHIV by the vaginal
route. Although SHIV162p4 is well characterized for vaginal infection, there are no reports on RT-SHIV
infection by a mucosal route. Six macaques will be used to determine the minimal infectious dose of RTSHIV
by the vaginal route. 3. To test the efficacy of RC-101 as a vaginal microbicide against SHIV162p4.
Twelve female rhesus macaques will be used to test prevention of transmission by vaginal silicone ring
application containing RC-101 4. To test the efficacy of CSIC, a non-nucleoside RT inhibitor against vaginal
challenge with RT-SHIV. Twelve female rhesus macaques will be used to test prevention of transmission by
CSIC containing silicone rings. 5. To test the efficacy of the combination of CSIC and RC-101.The final plan
is to deliver both drugs in the same ring formulation. The goal is to show that these 2 drugs can be used
together and will afford better protection against HIV-1 vaginal infection than either could alone.
All animals will be monitored for infection for 6 months. This is a highly collaborative project that will closely
coordinate with all other projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE
-
批准号:8358057
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY
-
批准号:8358091
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES
-
批准号:8358058
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
EFFICACY AND TOXICITY OF CSIC AND RETROCYCLIN IN THE SIV VAGINAL CHALLENGE MODEL
-
批准号:8358131
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
Primate Studies
-
批准号:8720871
-
项目类别:
-
资助金额:$22.05万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
PATHOGENESIS OF NATURAL SIV AND STLV INFECTIONS IN HUMANS
-
批准号:8358130
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
ISOLATION OF A NEW HIV-2 GROUP IN THE US
-
批准号:8358116
-
项目类别:
-
资助金额:$5.78万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
NHP PILOT STUDY OF A NOVEL PROTEIN ADJUVANT FOR VACCINES AGAINST HUMAN PATHOGENS
-
批准号:8358134
-
项目类别:
-
资助金额:$3.2万
-
财政年份:2011
-
负责人:Preston A Marx
-
依托单位:
HIV ENV EPITOPE ENGINEERING
-
批准号:8173047
-
项目类别:
-
资助金额:$3.94万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY
-
批准号:8172993
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
EFFICACY AND TOXICITY OF CSIC AND RETROCYCLIN IN THE SIV VAGINAL CHALLENGE MODEL
-
批准号:8173044
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES
-
批准号:8172951
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
ELICITATION OF BROAD IMMUNITY USING VLPS WITH CONSENSUS ENVS
-
批准号:8173016
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE
-
批准号:8172950
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
NHP PILOT STUDY OF A NOVEL PROTEIN ADJUVANT FOR VACCINES AGAINST HUMAN PATHOGENS
-
批准号:8173048
-
项目类别:
-
资助金额:$3.94万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
PATHOGENESIS OF NATURAL SIV AND STLV INFECTIONS IN HUMANS
-
批准号:8173043
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
ANTIBODY EFFECTOR FUNCTION PROTECTION AGAINST HIV-1
-
批准号:8172954
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
PALOMA PHARMA 529 TREATMENT FOR SIV STUDY
-
批准号:8173042
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2010
-
负责人:Preston A Marx
-
依托单位:
SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES
-
批准号:7958652
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2009
-
负责人:Preston A Marx
-
依托单位:
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES
-
批准号:7958614
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2009
-
负责人:Preston A Marx
-
依托单位:
海外基金